Motesanib and advanced NSCLC: experiences and expectations

Bibliography

• Jemal A, Siegel R, Xu J, Cancer Statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
   Google Scholar
• Wahbah M, Boroumand N, Castro C, Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007;11:89-96
   PubMed Web of Science ®Google Scholar
• Spiro SG, Rudd RM, Souhami RL, Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-36
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Algire GH. Vascular reactions of normal and malignant tissues in vivo. VII. Observations on vascular reactions in destruction of tumor homografts. J Natl Cancer Inst 1954;15:483-91
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-88
   PubMed Web of Science ®Google Scholar
• Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16
   PubMed Web of Science ®Google Scholar
• Senger DR, Van de Water L, Brown LF, Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5
   PubMed Web of Science ®Google Scholar
• Connolly DT, Heuvelman DM, Nelson R, Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8
   PubMed Web of Science ®Google Scholar
• Karpanen T, Egeblad M, Karkkainen MJ, Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90
   PubMed Web of Science ®Google Scholar
• Brown LF, Berse B, Jackman RW, Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62
   PubMed Web of Science ®Google Scholar
• Brown LF, Berse B, Jackman RW, Expression of vascular permeability factor (vascular endothelial growth factor)and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35
   PubMed Web of Science ®Google Scholar
• Ohta Y, Endo Y, Tanaka M, Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996;2:1411-16
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J Clin Oncol 2008;26:2013-19. Erratum in: J Clin Oncol 2009;27:653, J Clin Oncol 2008;26:3110
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. Erratum in: N Engl J Med 2007;356:318
   PubMed Web of Science ®Google Scholar
• Goss GD, Arnold A, Shepherd FA, Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55
   PubMed Web of Science ®Google Scholar
• Glade BJ, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004;7:289-300
   PubMed Web of Science ®Google Scholar
• Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-20
   PubMed Web of Science ®Google Scholar
• Herbst RS, O'Neill VJ, Fehrenbacher L, Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-50
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-26
   PubMed Web of Science ®Google Scholar
• Socinski MA, Novello S, Brahmer JR, Multicenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
   PubMed Web of Science ®Google Scholar
• Polverino A, Coxon A, Starnes C, AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66:8715-21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Kurzrock R, Mulay M, Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369-76
   PubMed Web of Science ®Google Scholar
• Li C, Kuchimanchi M, Hickman D, In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos 2009;37:1378-94
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Reckamp K, Stephenson GJ, Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010;16:279-90
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kabbinavar F, Menon H, A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011. [Epub ahead of print]
   Google Scholar
• Amgen. A Phase 3, multicenter, randomized, placebo-controlled, double-blind trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer. ClinicalTrials.gov NCT00460317. Available from: http://clinicaltrials.gov/ct2/show/NCT00460317?term=motesanib+and+lung+cancer&rank=3 [Last accessed 13 April 2011]
   Google Scholar
• Dingemans AM, de Langen AJ, van den Boogaart V, First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2011;22:559-66
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Gatzemeier U, Fossella F, Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-80
   PubMed Web of Science ®Google Scholar
• Sawaki A, Yamada Y, Komatsu Y, Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol 2010;65:961-7
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz JP, Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Wheeler DL, Armstrong EA, Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res 2010;16:3639-47
   PubMed Web of Science ®Google Scholar
• Bass MB, Sherman SI, Schlumberger MJ, Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95:5018-27
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008;14:6371-5
   PubMed Web of Science ®Google Scholar